EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration

Scott Friedman, Nikolas London, Jan Hamouz, Ágnes Kerényi, Andras Papp, Tamás Pregun, Vincent Chow, Bianca Bautista, Daidong Wang, Gary Grachev, Janet Franklin

Ophthalmology Retina · 2026

DOI: 10.1016/j.oret.2025.07.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2026. Verfasst von Scott Friedman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Florida Retina Consultants, Lakeland, Florida. Electronic address: smfriedman83@hotmail.com. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Visual Acuity, Wet Macular Degeneration. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVisual AcuityWet Macular DegenerationBiosimilar PharmaceuticalsHumansMaleFemaleDouble-Blind MethodIntravitreal InjectionsAgedTreatment OutcomeAngiogenesis InhibitorsMiddle AgedTomography, Optical CoherenceAged, 80 and overFollow-Up StudiesDose-Response Relationship, DrugVascular Endothelial Growth Factor AFluorescein AngiographyFundus OculiMacula Lutea

Stichwörter der Autor:innen

ABP 938AfliberceptAlibercept-ayyhBiosimilarNeovascular age-related macular degeneration

Substanzen

afliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsBiosimilar PharmaceuticalsAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Florida Retina Consultants, Lakeland, Florida. Electronic address: smfriedman83@hotmail.com.
  • Retina Consultants of San Diego, San Diego, California.
  • Department of Ophthalmology, University Hospital Královské Vinohrady, Prague, Czech Republic.
  • Department of Ophthalmology, Bajcsy-Zsilinszky University Teaching Hospital, Budapest, Hungary.
  • Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
  • Amgen Inc, Thousand Oaks, California.

Förderung

  • Amgen Inc

Zitieren

APA

Friedman, S., London, N., Hamouz, J., Kerényi, Á., Papp, A., Pregun, T., Chow, V., Bautista, B., Wang, D., Grachev, G., & Franklin, J. (2026). Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2025.07.015

Vancouver

Friedman S, London N, Hamouz J, Kerényi Á, Papp A, Pregun T, et al. Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 2026. doi:10.1016/j.oret.2025.07.015

BibTeX
@article{Friedman2026,
  author = {Friedman, Scott and London, Nikolas and Hamouz, Jan and Kerényi, Ágnes and Papp, Andras and Pregun, Tamás and Chow, Vincent and Bautista, Bianca and Wang, Daidong and Grachev, Gary and Franklin, Janet},
  title = {Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration},
  journal = {Ophthalmology Retina},
  year = {2026},
  doi = {10.1016/j.oret.2025.07.015}
}
Kostenlos starten →